AddThis

FDA grants Barr final approval on generic Mirapex

Related Content

No related items were found.

MONTVALE, N.J. Barr Pharmaceuticals has received final approval from the Food and Drug Administration for a generic version of Boehringer Ingelheim Pharmaceuticals Parkinson’s disease Mirapex, according to the Associated Press.

The generic, pramipexole dihydrochloride will be available in 0.125 mg, 0.25 mg, 0.5 mg, 1 mg and 1.5 mg.

Before the company can launch the generic, it has to win a patent challenge it filed against Boehringer. The trial is set to begin on March 10, in the District Court in Delaware.

Mirapex had sales of about $324 million for the 12 months that ended in August 2007, according to Barr.

© 2014 Drug Store News. All Rights Reserved.